Decheng Capital is a cross-border China-US life sciences specialist that leads or co-leads pivotal rounds for companies with first-in-class mechanisms in areas like CRISPR, next-generation diagnostics, and precision oncology. The firm's partners bring Wall Street equity research backgrounds to early-stage venture investing and are recognized by portfolio companies and co-investors as expert biotech partners rather than generalist VCs.